Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
4(50%)
Results Posted
50%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
1
13%
Ph phase_2
6
75%
Ph phase_3
1
13%

Phase Distribution

1

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
6(75.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

4

trials recruiting

Total Trials

8

all time

Status Distribution
Active(5)
Completed(2)
Terminated(1)

Detailed Status

Active, not recruiting2
Completed2
Recruiting2
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
4
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 26 (75.0%)
Phase 31 (12.5%)

Trials by Status

active_not_recruiting225%
not_yet_recruiting113%
terminated113%
completed225%
recruiting225%

Recent Activity

4 active trials
Showing 5 of 8
not_yet_recruitingphase_2

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma

NCT07741877
recruitingphase_3

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

NCT06743126
terminatedphase_2

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

NCT03645928
completedphase_2

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

NCT06151847
active_not_recruitingphase_2

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

NCT07288203
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07741877Phase 2

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma

Not Yet Recruiting
NCT06743126Phase 3

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Recruiting
NCT03645928Phase 2

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Terminated
NCT06151847Phase 2

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Completed
NCT07288203Phase 2

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Active Not Recruiting
NCT02360579Phase 2

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Completed
NCT05176470Phase 1

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Active Not Recruiting
NCT06481592Phase 2

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

Recruiting

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8